Actuate Therapeutics (NASDAQ: ACTU) has announced the publication of new data in Nature Medicine from its Phase 2 clinical trial evaluating elraglusib in combination with the gemcitabine-Nab-paclitaxel (GnP) chemotherapy compared to GnP alone in patients with previously untreated metastatic pancreatic cancer (mPC).
The peer-reviewed paper is titled “Elraglusib and Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma: A Randomized Controlled Phase 2 Trial.”
In a statement, Daniel Schmitt, CEO of Actuate, commented, “These Phase 2 results continue to reinforce elraglusib’s potential as a combination-ready, first-line therapy with the ability to enhance the activity of standard of care chemotherapeutic backbones. The significant improvement in overall survival with an acceptable safety profile marks an important milestone for patients facing metastatic pancreatic cancer, historically one of the most difficult to treat diseases. The elraglusib containing regimen delivered a 40% improvement in median overall survival, a 38% lower risk of death, and doubled the survival rate at one year compared to the current first-line chemotherapy regimen of GnP alone.”
He added, “By targeting a central signaling node such as GSK-3β, elraglusib may modulate tumor cell survival, reshape tumor microenvironment, and suppress adaptive resistance pathways, enabling a broader biological impact across a broad range of cancers. Importantly, we are also advancing our research focused on exploring the expected synergistic potential of elraglusib in combination with RAS and MEK/RAF inhibitors, with the goal of further enhancing anti-tumor activity and broadening elraglusib’s therapeutic potential for patients. We remain deeply committed to advancing treatments that can improve patients’ lives and are grateful to the investigators and families who made this study possible.”
